Clinical Trial Results:
Pharmacological treatment of hypersexual disorder; an open pilot study to evaluate the feasibility and effectiveness of treatment with Naltrexone
Summary
|
|
EudraCT number |
2018-001049-15 |
Trial protocol |
SE |
Global end of trial date |
29 Sep 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Jun 2021
|
First version publication date |
12 Jun 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
HD-TREX
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
ANOVA Karolinska University Hopsital
|
||
Sponsor organisation address |
Norra Stationsgatan 69, Stockholm, Sweden,
|
||
Public contact |
Josephine Savard, ANOVA (Andrologi, Sexualmedicin, Transmedicin), 46 851773200, josephine.savard@sll.se
|
||
Scientific contact |
Josephine Savard, ANOVA (Andrologi, Sexualmedicin, Transmedicin), 46 851773200, josephine.savard@sll.se
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
14 Apr 2020
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
29 Sep 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
29 Sep 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The aim of this pilot study is to assess feasibility, efficacy and tolerability of Naltrexone treatment in patients with hypersexual disorder. The following research questions will be asked:
1. Is treatment with Naltrexone feasible for patients with Hypersexual disorder treated at a sub specialized unit?
2. Does Naltrexone reduce symptoms in patients with Hypersexual disorder? And if so, what clinical characteristics predict response?
3. What is the tolerability of Naltrexone in patients with Hypersexual disorder?
|
||
Protection of trial subjects |
Blood chemistry and adverse event monitoring
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Sep 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Sweden: 20
|
||
Worldwide total number of subjects |
20
|
||
EEA total number of subjects |
20
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
20
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Patients seeking treatment due to troubled sexual behavior | ||||||
Pre-assignment
|
|||||||
Screening details |
37 men were screened, 20 were recrutied, 17 did not beet inclusion criteria mainly due to not meeting diagnose criteria | ||||||
Pre-assignment period milestones
|
|||||||
Number of subjects started |
20 | ||||||
Number of subjects completed |
20 | ||||||
Period 1
|
|||||||
Period 1 title |
overall trial (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
main arm | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
naltrexone
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Coated tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
25-50 mg daily use
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
full anaysis
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
all subjects
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
main arm
|
||
Reporting group description |
- | ||
Subject analysis set title |
full anaysis
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
all subjects
|
|
||||||||||
End point title |
main end point | |||||||||
End point description |
||||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
after 4 weeks of treatment
|
|||||||||
|
||||||||||
Statistical analysis title |
paired sample t-test | |||||||||
Statistical analysis description |
Longitudinal data of same group (n=20) at two time points
|
|||||||||
Comparison groups |
main arm v full anaysis
|
|||||||||
Number of subjects included in analysis |
40
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
equivalence | |||||||||
P-value |
< 0.05 | |||||||||
Method |
t-test, 2-sided | |||||||||
Parameter type |
Mean difference (final values) | |||||||||
Point estimate |
5.95
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
3.9 | |||||||||
upper limit |
8 | |||||||||
Variability estimate |
Standard deviation
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
After 3-5 days with medication, weekly in the web-based plattform and at a consultation after 4 weeks. After 8 weeks (follow-up) adverse events were assessed. Bloodsamples were collected at baseline and after 4 weeks.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
PI designed | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
sponsor
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/32532705 |